KRAS and pancreatic neoplasm: Activating K-Ras mutations are present in nearly all PDACs (up to 90%) and occur very early and are the most frequent mutations in pancreatic cancer, followed by mutation or silencing of p53, p1, and DPC4/smad4 [17], [18].